Opdivo (Nivolumab) Dosing Protocol
Opdivo (nivolumab) can be administered using multiple FDA-approved dosing regimens: 240 mg IV every 2 weeks, 480 mg IV every 4 weeks, or weight-based dosing at 3 mg/kg every 2 weeks—all are therapeutically equivalent with comparable safety and efficacy profiles. 1
Approved Dosing Schedules
The FDA-approved dosing options for Opdivo monotherapy include:
- 240 mg IV every 2 weeks (Q2W)
- 480 mg IV every 4 weeks (Q4W)
- 3 mg/kg IV every 2 weeks (weight-based)
All regimens are administered as 60-minute IV infusions, though 30-minute infusions produce comparable drug exposure 1. The 480 mg Q4W schedule was approved based on pharmacokinetic modeling demonstrating that it achieves similar time-averaged steady-state concentrations as the 3 mg/kg Q2W regimen, with only 16% lower trough levels and 45% higher peak levels—both within acceptable therapeutic ranges 2, 3.
Disease-Specific Protocols
For Melanoma (Adjuvant Setting)
Nivolumab 240 mg IV every 2 weeks OR 480 mg IV every 4 weeks for 52 weeks 4
For Unresectable/Metastatic Melanoma (Monotherapy)
Nivolumab 240 mg IV every 2 weeks OR 480 mg IV every 4 weeks until disease progression 4
Alternative weight-based option: 3 mg/kg IV every 2 weeks 4
Combination with Ipilimumab (Melanoma)
Standard regimen: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks 4
Alternative flat-dose regimen: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg every 2 weeks 4
Neoadjuvant Setting (Stage III Melanoma)
Based on the PRADO trial design, the "flip-dose" regimen shows optimal balance of efficacy and tolerability: Nivolumab 3 mg/kg + ipilimumab 1 mg/kg IV every 3 weeks for 2 doses 5. This regimen achieved 77% pathologic response rate with only 20% grade 3-4 immune-related adverse events, compared to 40% toxicity with the standard 1 mg/kg nivolumab + 3 mg/kg ipilimumab dosing 5.
Key Pharmacokinetic Considerations
- Steady-state is reached by 12 weeks when using the every-2-week schedule 1
- Half-life is 25 days, supporting extended dosing intervals 1
- No dose adjustments needed for age (29-87 years), weight (35-160 kg), sex, race, mild-to-moderate hepatic impairment, or renal impairment (eGFR ≥15 mL/min/1.73 m²) 1
- Severe hepatic impairment has not been studied 1
Clinical Equivalence of Dosing Schedules
The 480 mg Q4W regimen produces 5.2% higher average steady-state concentration and 15.6% lower trough concentration compared to 3 mg/kg Q2W, differences that are not clinically meaningful 3. Real-world data from 342 melanoma patients showed no significant difference in grade ≥3 immune-related adverse events between weight-based Q2W and fixed-dose Q4W regimens (hazard ratio 0.54,95% CI 0.21-1.36, p=0.19) 6. A separate multicenter study of 348 patients confirmed comparable safety profiles with grade ≥3 immune-related adverse event rates of 13.1% versus 11.7% (p=0.8) for weight-based versus flat-dose regimens 7.
Practical Advantages of Q4W Dosing
The every-4-week schedule offers:
- Reduced healthcare utilization with half the number of infusion visits
- Lower nursing and pharmacy workload
- Decreased patient time burden and travel
- Cost savings from reduced hospitalization 6, 8
Common Pitfalls to Avoid
- Do not use severe hepatic impairment patients without alternative data—this population was excluded from pharmacokinetic studies 1
- Do not assume higher doses are more effective—exposure-response analyses show no benefit to doses above the approved range 1
- Monitor for immune-related adverse events regardless of schedule—toxicity profiles are equivalent across dosing regimens 6, 7
- In neoadjuvant settings, prefer the flip-dose combination (nivolumab 3 mg/kg + ipilimumab 1 mg/kg) over standard dosing to minimize grade 3-4 toxicity while maintaining efficacy 5